OBJECTIVES: Primary spontaneous pneumothorax frequently recurs after chest tube management. Evidence is lacking whether patients may benefit from surgery following their first episode.
INTRODUCTION
Primary spontaneous pneumothorax (PSP) commonly affects young otherwise healthy individuals [1] and frequently leads to readmissions due to recurrence [2] , which may occur in up to 54% following conventional chest tube treatment [3] . According to international guidelines [4, 5] , observation, simple aspiration and chest tube treatment, with or without suction, are established first-line treatments of the first episode of PSP, whereas further investigation with computed tomography and preventive video-assisted thoracoscopic surgery (VATS) is reserved for recurrent pneumothorax [6, 7] . However, despite existing clinical practice guidelines [4, 5] , many thoracic surgeons now offer VATS to patients with their first presentation of PSP, and optimal management remains controversial [8] . At the core of the ongoing controversy remains the question whether there are high-risk patients of recurrence, who should be offered primary preventive surgery following the first episode of PSP, and whether there are any predictors to identify these high-risk patients. A literature search identified 1 recent randomized controlled trial comparing VATS with chest tube treatment in PSP patients [9] . Although it was limited by small sample size, it favoured VATS. Parallel to their trial, we did a similar randomized trial and analysed the potential role of high-resolution computed tomography (HRCT) as a non-invasive diagnostic tool to identify high-risk patients.
MATERIALS AND METHODS

Study design and participants
We performed a randomized controlled, multicentre trial at the 3 public university-based cardiothoracic surgery departments in western Denmark. This trial was approved by the Regional Ethics Committee of Southern Denmark (Project-ID S-20090052) and the Danish Data Protection Agency (J.nr. 2009-41-3493). This study was registered and approved by www.Clinicaltrials.gov (reference ID NCT 02866305). It was conducted in accordance with the Declaration of Helsinki, and written informed consent was obtained from all patients.
We recruited patients in western Denmark admitted with their first episode of PSP verified by chest radiography. Eligible patients were young otherwise healthy individuals between 18 and 40 years of age and admitted to the hospital within a 7-year period (from 1 August 2009 to 4 November 2016). On the basis of instructions from the ethics committee, we excluded minors (<18 years of age). Furthermore, patients with previous pneumothorax and secondary spontaneous pneumothorax were excluded. Patients older than 40 years were excluded to avoid bias from unacknowledged underlying comorbidity. Exclusion criteria also included pregnancy, breastfeeding, previous chest surgery, known contraindications for general anaesthesia and lacking ability to understand the information and consequence of randomization. Finally, patients who presented with a small and asymptomatic pneumothorax that was treated by observation only and did not require initial chest tube management were omitted for ethical reasons.
Inclusion and randomization
In western Denmark, PSP is treated either at the local county hospital or at 1 of the 3 university departments of cardiothoracic surgery. On admittance at either of the hospitals, appointed local investigators were in charge of the initial treatment and they decided whether chest tube drainage was indicated according to the standard of care for acute pneumothorax. The local investigators screened all and identified and informed eligible patients. Patients admitted to county hospitals who accepted inclusion were subsequently transferred to the regional cardiothoracic surgery department to ensure uniform cardiothoracic surgical treatment.
On arrival at 1 of the 3 cardiothoracic departments, chest radiography was used to ensure the correct placement of the chest tube. Furthermore, the initial treatment was evaluated and optimized, and sufficient analgesics were administered to allow full mobilization. When chest radiography confirmed complete expansion of the lung, HRCT was performed within 24 h. Based on the presence of bullae > _1 cm (yes/no), patients were stratified into 2 cohorts, and each cohort was randomly assigned to either continued conventional chest tube management or a VATS bullectomy with mechanical pleurodesis during the initial admission or as an elective procedure within 4 weeks. Following informed consent, HRCT examination randomization was done by either the principal investigator or 1 of the 2 assistant investigators at the other 2 cardiothoracic surgical departments in a ratio 1:1. Allocation concealment was achieved with a web-based computer-generated randomization module (www.randomize.dk). If air leakage persisted for more than 5 days, despite optimal chest tube drainage, the patient was offered preventive surgery according to national general thoracic surgery traditions. For the same reason, patients were excluded from this study if they were not referred within the first 5 days of initial chest tube drainage. If the lung never unfolded properly, despite optimal treatment, the HRCT was not considered possible to interpret, and the patient was excluded. Eligible patients, who denied participation in this trial and patients who were treated by observation only, were asked to complete a 'drop-out questionnaire' to account for the entire cohort and to allow comparison to determine whether the study population was representative.
Baseline characteristics collected were age, smoking history, education, employment, medical history and onset of symptoms in a questionnaire presented on admittance.
Procedures and follow-up
The removal of chest tubes was performed based on a strict algorithm and required complete cessation of any air leakage and fluid output <250 ml (clear fluid) per 24 h.
In patients allocated to VATS, we used a 3-port technique with a 10-mm inferior camera port and a 30 -angulated thoracoscope (Olympus Endo-Eye, Olympus, Hamburg, Germany). All VATSs were strictly monitor based without any use of rib spreading. We performed bullectomy of all visible blebs/bullae, and if none were identified, we routinely resected the apical part of the upper lobe based on local traditions. We used mechanical staplers in all operations and performed a mechanical pleurodesis of all visible pleura parietale with a dedicated tool 'MICTEC Pleural abrader' (Düfner Instruments, Tuttlingen, Germany). All surgical procedures were performed in the presence of an experienced board-certified general thoracic surgeon.
A 3-h stay in the recovery unit was the standard of care for postoperative monitoring. The chest tube removal in the surgical patients was performed based on the same criteria as for conservatively treated patients. All surgical patients received an epidural catheter before surgery, which was used until the chest tube was removed or no later than 4 days after surgery. After removal of the chest tube in VATS patients, we used slow-release morphine tablets (10 mg 3 times a day), but we abstained from non-steroidal anti-inflammatory drug to optimize the mechanical pleurodesis [10] . Oral analgesics were gradually reduced during 2 weeks after discharge until complete cessation.
Patients were always discharged with a fully expanded lung on chest radiography. All patients visited the outpatient clinic at their regional cardiothoracic surgical department 4 weeks after discharge for follow-up. In patients allocated to VATS, follow-up was 4 weeks post-surgery.
We asked all patients to complete a follow-up questionnaire (self-constructed) at 4 weeks and 1 year after discharge, focusing on any episodes of recurrent pneumothorax. Furthermore, performance state, anxiety level and smoking habits were evaluated using the Likert scales and pain/discomfort by the visual analogue scale. In this article, we only present data concerning the primary end point 'ipsilateral recurrence'. Remaining data will be presented when all included patients have completed a 1-year follow-up. To ensure a high response rate, we offered all patients to receive questionnaires by mail (web-based version), by postal delivery or by telephone interview by the principal investigator. All the original paperwork and a copy of all patient charts and HRCTs were progressively collected by the principal investigator and stored under lock and key in the research unit of the Cardiothoracic Surgical Department, Odense University Hospital, Odense. Full trial protocol can be requested from the principal investigator.
High-resolution computed tomography
To ensure uniformity, HRCT was done according to a specific protocol without contrast using a multislice 64-row computed tomography scanner with spiral acquisition. Primary analysis was done according to the original stratification based on the HRCT interpretation by the experienced local cardiothoracic radiologist. In addition and according to the most recent literature [11, 12] , we did a sub-analysis taking the exact bullae size and the dystrophic severity score (DSS) into account in an attempt to identify possible predictors of recurrence. Therefore, all HRCT scans were re-reviewed independently by the principal investigator (W.H.O.) and by a senior radiologist (P.E.A.) to ascertain the presence and actual size of blebs/bullae. Blebs were defined as air-filled lesions <1 cm and bullae > _1 cm. We assessed dystrophic lesions by type, distribution and number to calculate the ipsilateral DSS [11, 12] (Table 1) .
We then stratified patients into 2 subgroups 'low-grade' (DSS 0 + 3) and 'high-grade' (DSS 4-5). Finally, to determine whether bullae size was an independent predictor of recurrence, we stratified the patients into 4 groups [(i) no lesions, (ii) blebs < 1 cm, (iii) bullae > _1-<2 cm and (iv) bullae > _2 cm] based on the size of the largest visible ipsilateral lesion.
Outcomes
The primary end point was ipsilateral recurrent spontaneous pneumothorax verified by chest radiography. Secondary end points were complications and length of hospitalization.
Statistical analysis
On the basis of available publications in 2009 [13] [14] [15] , we anticipated a lower ipsilateral recurrence rate following VATS than that after conventional chest tube drainage with an expected recurrence rate of 5% and 25%, respectively. We aimed to detect a clinically relevant difference of 20% in the ipsilateral recurrence rate over time, and with a 5% significance level and a power of 80%, we calculated that 75 patients were necessary in each group (http://www.stat.uiowa.edu/rlenth/Power). We planned to perform an interim analysis when the first 150 enrolled patients had completed 1-year follow-up given that all 4 subgroups had at least 50% of the intended inclusions (38 patients in each group). In case of crossover, the patients were analysed according to the principle of 'intention to treat'. If the interim analysis confirmed a statistical significant difference between the 2 treatments, the study would be terminated for ethical reasons.
We used the Mann-Whitney test to compare categorical data and the v 2 test to compare numerical proportions. Patients were included in the analysis with the available data, and we did not attempt to estimate missing data. Initially, we performed a multivariate logistic regression analysis to investigate the overall effect of VATS intervention by each cardiothoracic centre without taking the risk time into account. The dependent variable was recurrence (yes/no), and the explanatory variables were allocated treatment (conventional chest tube treatment or VATS), bulla size (<1 cm or > _1 cm) and treating cardiothoracic centre (1-2-3). Then, we used the Cox regression analysis to take the risk time into account and evaluated the effect of VATS stratified by bullae size (<1 cm or > _1 cm). The Cox regression analysis was used to identify independent predictors of recurrence, initially on demographic characteristics, then in a subanalysis on DSS and bullae size, and finally a trend analysis was performed to investigate a possible size-response relationship for blebs/bullae. The proportional hazard assumption was ensured for all the Cox regression analysis. Data were analysed using STATA [16] (Release 13; StataCorp LP).
RESULTS
Between 1 August 2009 and 4
November 2016, we screened 457 patients admitted with PSP ( Fig. 1) . We excluded 84 patients in accordance with exclusion criteria and identified 373 patients eligible for inclusion. Of these patients, 59 were not willing to participate in the trial, and 81 patients were eligible but for unknown reasons were not asked to participate. In 51 patients, the referral to the regional cardiothoracic centre was delayed more than 5 days, and therefore, they were excluded. One patient was excluded because the affected lung did not unfold properly despite optimal chest tube treatment, and therefore, we abstained from HRCT and she underwent primary preventive surgery instead.
Of the 181 enrolled patients, 151 were men and 30 women (ratio = 5.0). Eighty-eight patients were randomly assigned to VATS and 93 to conservative chest tube treatment (Fig. 1) . Because we did not use block randomization, this interim analysis reflects that patients were not allocated equally between the 4 subgroups (Fig. 1) . The 276 excluded patients returned 249 questionnaires with complete data. Another 5 patients returned questionnaires with incomplete data and 22 refused to complete the questionnaire. The 181 enrolled patients were slightly older than the excluded patients: 26.2 years [95% confidence interval (CI) 25.3-27.1] vs 24.1 years (95% CI 23.3-24.9, P = 0.012), but they did not differ from the excluded patients regarding sex (P = 0.13), smoking habits (P = 0.75), affected lung (P = 0.42) or body mass index (P = 0.22).
Clinical characteristics and treatment
Baseline characteristics of the 181 enrolled patients revealed more daily smokers in patients with large bullae > _1 cm versus those with small blebs (P < 0.001, Table 2 ). No other demographic differences were observed between the 2 cohorts ( Table 2) . Fiftyseven (31%) patients were referred from a county hospital and 124 (69%) patients were admitted directly to 1 of the 3 cardiothoracic centres.
No major complications were reported in the patients allocated to conservative treatment. However, 12 (13%) patients allocated to conservative treatment required more than 1 chest tube insertion during their first admittance, and in 38 (42%) patients, suction was applied to fully expand the lung. Twenty-seven (31%) surgical procedures were performed during the primary admittance, and 61 (69%) were postponed as elective procedures shortly after [mean 17 days (SD 15.2)]. Three (3%) surgical patients underwent reoperation due to bleeding from the intercostal artery in one of the portholes. Following reoperation, their treatment was uneventful, and no other complications were reported in the surgical patients.
Eight patients crossed over from conservative chest tube treatment to VATS due to prolonged air leakage despite optimal chest tube treatment. Three patients crossed from the VATS cohort to conservative chest tube cohort due to medical reasons. In 2 patients, surgery was omitted due to severe anxiety. In 1 patient, an underlying lung disorder was suspected based on the HRCT, and he was referred to the regional centre for respiratory disease, but 6 months later, he was cleared of all suspicion. In addition, 2 (7%) female patients were later diagnosed with catamenial pneumothorax, and they both remained in the study according to the 'intention-to-treat' principle.
Length of hospitalization at first admittance was not significantly different (P = 0.42) following either treatment: 4.1 days (95% CI 3.4-4.8) in the surgical group and 3.8 days (95% CI 3.0-4.3) after chest tube management. However, if we included the time spent in the hospital in the 61 surgical patients who were readmitted for elective surgery according to randomization, the surgical patients had a significantly higher median accumulated hospital stay: 7.1 days (95% CI 6.4-7.9, P < 0.001).
Recurrence rate
At complete 1-year follow-up of the first 150 randomized patients, the median follow-up was 59 (range 9-97) months for all 181 included patients. During the study period, 43 (23%) patients presented with ipsilateral recurrence: recurrence occurred in 32 (34%) patients following chest tube treatment versus 11 (13%) patients after VATS. The multivariate logistic regression analysis revealed that VATS had a significant impact on overall recurrence when compared with conventional chest tube treatment (P = 0.0012), and there was no difference in effect between the 3 treating cardiothoracic centres (P = 0.35).
The unadjusted Cox regression analysis stratified by the 4 subgroups only demonstrated a risk reduction in recurrence in patients with bullae > _1 cm treated with primary VATS (hazard ratio 0.3, P = 0.014, Table 3 and Fig. 2 ).
Considering all conservatively managed patients versus VATS in a Cox regression analysis adjusted by allocated treatment and bullae size, the only significant predictor of recurrence was allocation to conservative treatment (P = 0.0011). Daily smokers had a lower risk when compared with never smokers (P = 0.0401). Sex, body mass index and debut age were not significant predictors (Table 3) . Considering each treatment isolated allowed us to investigate potential predictors of recurrence following either treatment (Table 4) . In conservatively treated patients, daily smokers had at lower risk compared with never smokers (P = 0.014) no other predictors were identified but we observed a trend towards larger bullae being at higher risk of recurrence 34 (17) 13 (5) 35 (15) 12 (6) (hazard ratio 2.4, P = 0.045). No independent predictors of recurrence were detected in the surgical patients (Table 4) . The potential association between dystrophic lesions (blebs or bullae) and recurrence was investigated in a sub-analysis by Cox regression (Table 5) . We confirmed a significant size-response relationship in conservatively treated patients (P = 0.014). The results indicated conservatively treated patients with bullae > _2 cm as high-risk patients (hazard ratio 4.4, P = 0.045). Ipsilateral DSS was not a significant predictor (P = 0.078).
DISCUSSION
The main finding in this trial was that patients admitted with their first presentation of PSP had a significant lower recurrence rate following VATS when compared with conventional chest tube treatment (Table 3 and Fig. 2) . These results were in agreement with a recently published small study [9] , where the recurrence rate following conservative chest tube treatment was 40.9% when compared with 0% in the surgical patients. The principal difference between the 2 trials was that we performed a larger, multicentre trial with a longer observation time. Furthermore, we stratified our patients based on their primary HRCT, which was not used in the former study. In addition, we systematically accounted for all excluded patients and can document that enrolled patients were representative. When our study was initiated in 2009, there was limited knowledge about the role of HRCT in the investigation of PSP. Instead, a computed tomography scan was the preferred examination, and several studies indicated that the size and number of dystrophic lesions were important [17, 18] . A clinical relevant bullae was determined as a lesion with a diameter > _1 cm [19] , which is why we decided to stratify our patients into 2 groups according to the presence or absence of clinical significant bullae (> _1 cm).
When stratified by bullae size, VATS remained significant in patients with bullae > _1 cm but only close to significant in patients with blebs <1 cm ( Table 3 , Fig. 2) , suggesting that the presence of large-scale dystrophic lesions may be an independent risk factor for recurrence. Stratified by treatment, we observed that increased bullae size resulted in a higher recurrence rate in conservatively treated patients ( Table 5 ). As summarized in Table 5 , our results also indicated that the presence of at least 1 bullae >2 cm was an independent risk factor in patients treated conservatively. These observations are in accordance with previous non-randomized publications [11, 12] , but in contrast, we did not find ipsilateral DSS to be an independent risk factor (Table 5) . Interestingly, we discovered conservatively treated daily smokers were at significantly lower risk of recurrence when compared with never smokers (Table 4) . We have no explanation for this observation. It may be a chance observation as it contradicts previous findings [20] , but one may also speculate that never smokers who present with PSP may have a genetic predisposition that renders them at higher risk despite the lack of risk behaviour. Similar to previous non-randomized publications [11, 12] we could not identify any independent predictors of recurrence in the surgical patients (Table 4) . The majority of all recurrences occurred within the first 6-18 months (Fig. 2) .
We observed a recurrence rate of 13% in the surgically treated patients, which is in line with previous findings [6] and serves to illustrate that preventive surgery does not exclude the risk of recurrence. All surgical patients should be informed about this prior to surgery. We do not have a solid explanation for apparent failure in these surgical patients, but unidentified bullae during surgery may have caused recurrence, or new bullae may have formed over time. Although some publications indicate that recurrence rates may be lower (0-7%) if surgery is done through thoracotomy [6, 21] , VATS represents the treatment of choice due to its minimal invasiveness and cosmetic advantage in the young population [22] . However, VATS is not without complications: 3 surgical patients underwent reoperation due to bleeding. Similarly, surgery may lead to morbidity and pain in some patients [23, 24] . Based on a recent review [25] , thoracoscopic pleural abrasion is safer than the apical pleurectomy in the treatment of PSP and, therefore, should be preferred. This study [25] also indicated that thoracoscopic bullectomy should be preferred in the future without additional mechanical abrasion due to increased risk of postoperative pain. However, further largescale RCTs are needed to confirm the best procedure.
Including time spent in the hospital during elective surgery, the mean hospital stay was significantly higher in VATS patients. However, patients managed by chest tube accounted for a 3-fold higher ipsilateral readmission rate when compared with surgical patients. Previous non-randomized studies [26, 27] made similar observations and concluded that preventive VATS in patients with the first presentation of PSP would initially increase the cost per individual, but over time, it was justified financially because it significantly reduced the number of readmissions.
Limitations
At interim analysis, our results strongly favoured VATS over conservative management in all 3 cardiothoracic centres, and according to our protocol, we decided to stop inclusion for ethical reasons. This is a limitation of our study, because this left us with unequal number of participants in each subgroup. We only included patients from 3 of 4 national cardiothoracic surgical departments, and this limits our study. However, we have no reason to believe that the results would have been different from the fourth centre. For ethical reasons, we excluded PSP patients treated by observation only, and this may bias our results. However, previous studies [3] indicated that these patients tend to experience recurrence more often, but otherwise they do not differ significantly from other PSP patients, and therefore, we believe our results can be applied to these patients, but further studies are needed to confirm this.
CONCLUSION
In conclusion, VATS was an effective treatment to prevent ipsilateral recurrence in patients with the first presentation of PSP. We identified large bullae as an independent predictor for recurrence and recommend all future patients admitted with their first incident of PSP should undergo an HRCT, and if this reveals major dystrophic lesions larger than 2 cm, preventive surgery should be the standard of care.
